BridgeBio (BBIO) Insider Files Form 144 for Minor 876-Share Sale

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) – Form 144 filing dated 06/26/2025

An officer of BridgeBio Pharma, Hannah A. Valantine (joint tenancy with Denis Von Kaeppler), has filed a Form 144 giving notice of intent to sell 876 common shares through Morgan Stanley Smith Barney on or about 06/26/2025. At the last reported market price, the transaction is valued at $38,640.27.

Key details:

• Securities outstanding: 189,880,720 shares – the proposed sale equals roughly 0.0005 % of shares outstanding, indicating an immaterial impact on float.
• Acquisition history: The shares were originally purchased on 12/29/2021 in an open-market, cash transaction.
• Recent insider activity: In the past three months, the filer has executed four separate sales of 4,292 shares each (total 17,168 shares) generating about $686 k in gross proceeds. Even combined, these sales represent approximately 0.009 % of shares outstanding.
• Relationship to issuer: The filer is listed as an Officer; no additional role description is provided.

No material adverse information was asserted by the filer, and the signature attests compliance with Rule 144 and Rule 10b5-1 representations. The notice is classified as a LIVE submission.

Because the transaction size is de-minimis relative to the company’s capitalization, it is unlikely to influence valuation or liquidity. Nonetheless, investors monitoring insider sentiment may note the continuation of discretionary selling by an officer.

Insights

Securities Analyst

TL;DR: Very small Form 144 sale; negligible dilution; insider continues modest selling activity—overall neutral signal.

The proposed sale of 876 BBIO shares equates to 0.0005 % of outstanding stock—far below any threshold that could affect float or pricing. Even when aggregated with the 17,168 shares sold over the prior three months, the officer’s total disposition reaches only 0.009 % of shares outstanding. There is no indication these trades stem from deteriorating fundamentals; the filer expressly certifies lack of undisclosed adverse information. From a market perspective, volume of this magnitude is unlikely to move the share price and does not materially alter insider ownership levels. I view the event as routine liquidity management and therefore neutral for investors.

Corporate Governance Expert

TL;DR: Routine compliance filing; confirms insider adherence to Rule 144, insignificant governance impact.

Form 144 serves as an advance notice rather than an execution report. The officer’s intent to sell a fractional stake demonstrates adherence to disclosure rules and potentially a structured 10b5-1 plan, although the filing does not explicitly cite one. The frequency of recent small transactions suggests disciplined, rule-based selling rather than opportunistic divestiture. Governance risk remains low: no material holdings change, and representations of no undisclosed adverse information are reiterated. Consequently, the filing maintains transparency without triggering governance alarms.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001855608
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BRIDGEBIO PHARMA, INC.
SEC File Number	001-38959
Address of Issuer	3160 Porter Drive Suite 250 Palo Alto CALIFORNIA 94304
Phone	(650) 391-9740
Name of Person for Whose Account the Securities are To Be Sold	HANNAH A VALANTINE & DENIS VON KAEPPLER JT TEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	876	38640.27	189880720	06/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/29/2021	Open Market Purchase	Open Market			876	12/29/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
HANNAH A VALANTINE 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	06/10/2025	4292	171680.00

144: Remarks and Signature

Remarks
Date of Notice	06/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Valantine Hannah
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)